<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675205</url>
  </required_header>
  <id_info>
    <org_study_id>AGR_2014-33</org_study_id>
    <secondary_id>2014-005720-10</secondary_id>
    <nct_id>NCT02675205</nct_id>
  </id_info>
  <brief_title>Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm</brief_title>
  <acronym>TIC-TAC</acronym>
  <official_title>Ticagrelor Versus Clopidogrel for Platelet Inhibition in Patients Undergoing Neurovascular Stenting for Intracranial Aneurysm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      Part of interventional neuroradiology procedures for the treatment of selected cerebral
      aneurysms are now based on stenting. To reduce thromboembolic events, dual antiplatelet
      therapy (APT) combining aspirin and clopidogrel is proposed with close monitoring, since 1/3
      of the patients are low responders due to variation of the biological response to clopidogrel
      . Ticagrelor is used by few teams but has never been evaluated in a randomized controlled
      trial. It could be an option for APT due to more reproducible response with less
      interindividual variability and reduced monitoring. The aim of this study is to demonstrate
      the interest of ticagrelor for the dual APT for platelet inhibition, in patients undergoing
      neurovascular stenting for cerebral aneurysm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">September 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 16, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients requiring at least one change of drug or dose adjustment to achieve platlet functional inhibition</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cerebral Aneurysm</condition>
  <arm_group>
    <arm_group_label>clopidogrel-aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel: 75mg and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ticagrelor-aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor: 90 mg bid and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>clopidogrel: efficacy and safety in cerebral aneurysm stenting</description>
    <arm_group_label>clopidogrel-aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>ticagrelor:efficacy and safety in cerebral aneurysm stenting</description>
    <arm_group_label>ticagrelor-aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <arm_group_label>clopidogrel-aspirin</arm_group_label>
    <arm_group_label>ticagrelor-aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unruptured cerebral aneurysm

          -  elective endovascular treatment

          -  stenting required

          -  dual antiplatelet therapy required

        Exclusion Criteria:

        -none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence Salomon, M.D</last_name>
    <phone>(33)1 48 03 6431</phone>
    <email>lsalomon@fo-rothschild.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANNE GODIER, MD, PhD</last_name>
      <email>agodier@fo-rothschild.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

